Wolverine Stack Side Effects: What BPC-157 and TB-500 Research Reports

Reviewed by Thomas Okafor, Peptide Chemist · Last reviewed October 17, 2026

Look for Wolverine stack side effects online and you’ll find long lists of symptoms with confident percentages attached. Very little of it comes from studies. Most comes from forum posts and clinic pages, which mix real observations with guesswork and can’t show what caused what. This page sorts the evidence instead. Every finding below carries a label for where it came from, so you can see at a glance how much weight it can bear:

• 🧪 Lab: cells or tissue in a dish
• 🐭 Animal: rodents and other species
• 👤 Human: published studies in people
• 💬 Anecdotal: forum posts and self-reports

Both compounds are lab research reagents that no regulator has cleared for people; the full statement is in our Medical Disclaimer.

What’s in the Wolverine Stack

The Wolverine stack combines BPC-157, a 15-amino-acid peptide based on a protein in gastric juice, with TB-500, a short synthetic fragment of thymosin beta-4. It’s sold as two separate vials or as one premixed vial, and amounts differ between sellers. The certificate of analysis for a given batch is the only reliable record of which peptides a vial holds and in what amounts. Our Wolverine stack guide explains the formats. Add GHK-Cu to the same pair and you get the GLOW blend, which gets its own side effects guide soon.

Wolverine Stack Side Effects at a Glance: Evidence Table

Published research on the Wolverine stack’s ingredients reports few adverse findings, largely because so few people have been studied. Animal toxicology on BPC-157 found no toxic effects at tested amounts, small human reports recorded no adverse events, and most reported symptoms come from anecdotes.

No published study gives frequencies for these effects, so the table lists none. Percentage tiers on other sites don’t trace back to any study we could find. [image]

BPC-157: Adverse Findings by Study Type

BPC-157’s safety evidence comes from one animal toxicology program and three small human reports totaling 30 people. The animal program turned up nothing toxic at the amounts screened, and the human reports recorded no adverse events, though none was large or long enough to detect uncommon problems.

Animal Toxicology Studies

🐭 The main package is Xu and colleagues’ 2020 evaluation in Regulatory Toxicology and Pharmacology, which followed standard drug-development screening. The team looked for general toxicity, damage to genetic material and effects on pregnancy and offspring across four species. They reported no meaningful toxicity on any of those measures. Studies like this are designed to catch obvious harm before human testing, so they can’t speak to rare effects, long-term exposure or reactions specific to people.

Small Human Studies

👤 All published human data come from one US clinical group. In Lee and Burgess’s 2025 pilot, 2 healthy adults received intravenous BPC-157, and blood markers for the heart, liver, kidneys, thyroid and blood sugar stayed unchanged with no reported symptoms. A 16-person knee pain case series and a 12-person bladder pilot also recorded no adverse events. Neither had a comparison group or was built to track side effects systematically. Our BPC-157 side effects page goes through each study in detail.

TB-500 vs Thymosin Beta-4: Why the Safety Data Differ

TB-500 is a seven-amino-acid synthetic piece of thymosin beta-4, while the human safety studies tested the full 43-amino-acid protein. That means TB-500 has essentially no human safety data of its own. Findings for the whole protein may or may not apply to the fragment. 👤 Full thymosin beta-4. Healthy volunteers received intravenous Tβ4 in a placebo-controlled study by Ruff and colleagues, first as a single infusion and then daily for two weeks. They reported no dose-limiting toxicities or serious adverse events. A 2021 trial of a recombinant version in healthy Chinese adults found the same pattern. Tβ4 gels and eye drops have also been through phase 2 testing. TB-500. The FDA’s compounding review says it found no human exposure data at all for products containing the fragment. The agency adds that it “lacks important information regarding any safety issues raised by this drug.” The fragment keeps the protein’s actin-binding stretch, which is why it’s studied at all, but a short peptide can behave very differently in the body from a full protein. Our TB-500 guide explains the chemistry.

What Research Says About the Combination

One published study has tested BPC-157 and TB-500 together, in rats, and it didn’t look at side effects. People have never been studied on the pair. So any safety information about the Wolverine stack itself is extrapolated from separate studies of each compound. 🐭 In July 2026, researchers in Istanbul published a rat Achilles tendon study comparing BPC-157, TB-500 and both together in 32 animals over four weeks. It measured tendon strength and tissue quality. The pair performed no better than either peptide given alone, the authors reported, and adverse effects weren’t among the outcomes they tracked. Interactions between the two peptides remain untested. Our BPC-157 vs TB-500 comparison sets out how their research differs.

Forum and Anecdotal Reports: What’s Described and Why It’s Weak Evidence

Forum posts about the Wolverine stack commonly describe headaches, tiredness, nausea or stomach upset, dizziness and irritation where a product was applied. These are self-reports with no controls, so they can’t show whether a peptide, a contaminant, expectation or something unrelated caused them. 💬 Self-reports carry several built-in problems:

• Unknown product. Posters rarely know what their vial contained, and testing shows research peptides vary widely.
• Missing controls. With nobody in an untreated group for reference, there’s no way to separate effects from background symptoms.
• Expectation. Reading about side effects makes people more likely to notice and report them, a pattern known as the nocebo effect.
• Other factors. Training, sleep, diet, other substances and the injury itself can all produce the same symptoms.

None of this means the reports are invented. It means they’re questions for research, and they don’t answer anything on their own.

Theoretical Concerns Researchers Raise

Reviewers raise three theoretical concerns about BPC-157 and TB-500: their links to blood-vessel growth, the possibility of immune reactions to synthetic peptides, and unknown long-term effects. No study has tied any of them to harm, and none has been tested head-on. Blood-vessel growth. 🧪 BPC-157 activated VEGFR2, a key receptor for new vessel formation, in Hsieh and colleagues’ 2017 study. 🐭 Full Tβ4 also promotes vessel growth and cell movement in animal models. Because tumors depend on new blood vessels, reviewers ask whether either compound could affect existing tumor growth. No study has tested that, and no study has shown it. Immune reactions. 🏛️ The FDA says compounded products containing either peptide “may pose risk for immunogenicity for certain routes of administration,” meaning the immune system could recognize them as foreign, partly because of impurities and clumping. Long-term effects. The longest human observations of BPC-157 span weeks. Nobody has followed people for months or years, for either compound.

Purity and Contamination: The Risk the Studies Don’t Cover

Published studies used research-grade material under controlled conditions. Material sold outside those settings may hold a different peptide, more or less than labeled, leftover synthesis fragments or bacterial endotoxins. Reviewing each batch’s certificate of analysis is the best available check. When Michigan sports-medicine researchers Mendias and Awan gathered outside lab results for peptides sold to consumers, purity and fill amounts were all over the map, according to their 2026 preprint. For a two-peptide product, a useful certificate shows:

• HPLC purity for each peptide separately
• mass spectrometry confirming each peptide’s identity
• the measured amount of each peptide
• endotoxin testing (USP chapter <85>)
• a lot number matching the vial and a named testing lab

To confirm a report directly with its testing lab, follow our peptide COA verification guide.

Populations Excluded From or Not Studied in Research

Some groups are missing from the research entirely, which leaves their outcomes unknown:

• Pregnancy. No human study has included pregnant participants. Animal reproductive testing exists only for BPC-157.
• People under 18. All human studies enrolled adults.
• Active cancer. Given the blood-vessel questions above, this group’s absence from studies is a notable unknown.
• Older adults and chronic illness. Small studies didn’t report results for these groups separately.

Regulatory and Prohibited-List Status (as of October 17, 2026)

FDA approval. The FDA hasn’t approved BPC-157 or TB-500 for any purpose. Compounding. The FDA’s compounding safety-risk page once listed both peptides in Category 2, the group with significant safety concerns. As of its April 22, 2026 update, both appear among nominations that were withdrawn. On BPC-157, the agency wrote that it “lacks sufficient information to know whether the drug would cause harm when administered to humans.” FDA advisers voted in July 2026 in favor of both for the 503A Bulks List, as AJMC reported, and on October 15 an interim policy on peptide access reached the White House for review, AP reported. Sport. On the WADA Prohibited List, BPC-157 appears by name in section S0, while section S2 covers thymosin beta-4 and related compounds such as TB-500. Our guide to US peptide law explains each category.

FAQ

Is the Wolverine stack FDA-approved?

No. The FDA hasn’t approved either ingredient, and both are marketed for laboratory research only as of October 17, 2026.

What side effects have BPC-157 studies reported?

Animal toxicology in four species found no toxic effects at tested amounts. Three small human reports, 30 people in all, recorded no adverse events, though none was designed or large enough to detect uncommon effects.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a seven-amino-acid synthetic fragment of thymosin beta-4, a 43-amino-acid protein. Human safety studies tested the full protein, and the FDA says it has found no human exposure data for the fragment.

Have BPC-157 and TB-500 been studied together in humans?

No. The single combination study involved 32 rats and measured tendon repair, and no study in people had been published as of October 2026.

Is the Wolverine stack on the WADA prohibited list?

Both ingredients are. BPC-157 is named in section S0, and TB-500 falls under section S2 with other thymosin beta-4 derivatives.

Conclusion

The Wolverine stack’s safety record is mostly a record of what hasn’t been studied. The data that exist come from animals, a few dozen people and the full Tβ4 protein, which leaves the combination itself largely unexamined.